- Home
- AGL vs PHVS Comparison
AGL vs PHVS Comparison
Compare AGL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- PHVS
- Stock Information
- Founded
- AGL 2016
- PHVS 2015
- Country
- AGL United States
- PHVS Switzerland
- Employees
- AGL N/A
- PHVS N/A
- Industry
- AGL Managed Health Care
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- PHVS Health Care
- Exchange
- AGL Nasdaq
- PHVS Nasdaq
- Market Cap
- AGL 952.1M
- PHVS 980.9M
- IPO Year
- AGL 2021
- PHVS 2021
- Fundamental
- Price
- AGL $2.20
- PHVS $22.99
- Analyst Decision
- AGL Hold
- PHVS Buy
- Analyst Count
- AGL 20
- PHVS 6
- Target Price
- AGL $4.41
- PHVS $37.17
- AVG Volume (30 Days)
- AGL 3.1M
- PHVS 59.1K
- Earning Date
- AGL 08-05-2025
- PHVS 08-13-2025
- Dividend Yield
- AGL N/A
- PHVS N/A
- EPS Growth
- AGL N/A
- PHVS N/A
- EPS
- AGL N/A
- PHVS N/A
- Revenue
- AGL $5,988,958,000.00
- PHVS N/A
- Revenue This Year
- AGL N/A
- PHVS N/A
- Revenue Next Year
- AGL $10.12
- PHVS N/A
- P/E Ratio
- AGL N/A
- PHVS N/A
- Revenue Growth
- AGL 23.07
- PHVS N/A
- 52 Week Low
- AGL $1.50
- PHVS $11.51
- 52 Week High
- AGL $7.73
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- AGL 41.25
- PHVS 67.31
- Support Level
- AGL $2.21
- PHVS $17.63
- Resistance Level
- AGL $2.32
- PHVS $26.33
- Average True Range (ATR)
- AGL 0.12
- PHVS 1.70
- MACD
- AGL 0.02
- PHVS 0.65
- Stochastic Oscillator
- AGL 17.33
- PHVS 65.24
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.